| First Author | Luan Y | Year | 2022 |
| Journal | Sci Adv | Volume | 8 |
| Issue | 51 | Pages | eade1846 |
| PubMed ID | 36542718 | Mgi Jnum | J:340442 |
| Mgi Id | MGI:7413626 | Doi | 10.1126/sciadv.ade1846 |
| Citation | Luan Y, et al. (2022) TAp63 determines the fate of oocytes against DNA damage. Sci Adv 8(51):eade1846 |
| abstractText | Cyclophosphamide and doxorubicin lead to premature ovarian insufficiency as an off-target effect. However, their oocyte death pathway has been debated. Here, we clarified the precise mechanism of ovarian depletion induced by cyclophosphamide and doxorubicin. Dormant oocytes instead of activated oocytes with high PI3K activity were more sensitive to cyclophosphamide. Checkpoint kinase 2 (CHK2) inhibitor rather than GNF2 protected oocytes from cyclophosphamide and doxorubicin, as cyclophosphamide up-regulated p-CHK2 and depleted primordial follicles in Abl1 knockout mice. Contrary to previous reports, TAp63 is pivotal in cyclophosphamide and doxorubicin-induced oocyte death. Oocyte-specific Trp63 knockout mice prevented primordial follicle loss and maintained reproductive function from cyclophosphamide and doxorubicin, indicated by undetectable levels of BAX and cPARP. Here, we demonstrated that TAp63 is fundamental in determining the signaling of oocyte death against DNA damage. This study establishes the role of TAp63 as a target molecule of adjuvant therapies to protect the ovarian reserve from different classes of chemotherapy. |
